Celgene Stock price

Equities

CELG

Delayed Nasdaq 04:00:00 2019-11-20 pm EST 5-day change 1st Jan Change
108.2 USD +0.10% Intraday chart for Celgene -1.97% +68.89%
Sales 2017 13B Sales 2018 15.28B Capitalization 44.82B
Net income 2017 2.94B Net income 2018 4.05B EV / Sales 2017 6.61 x
Net Debt 2017 3.79B Net Debt 2018 14.22B EV / Sales 2018 3.86 x
P/E ratio 2017
28.7 x
P/E ratio 2018
11.6 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation CI
Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation CI
Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity CI
Celgene Corporation Issues Notice of Redemption of Notes CI
Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion CI
Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors CI
Amgen : Signs Licensing Agreement With Medicines Development for Global Health MT
Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook MT
Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors CI
Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors CI
Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene CI
Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors CI
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis CI
DISH Network : Democratic lawmaker presses antitrust enforcers on company ties, settlements RE
Galecto, Inc. acquired PharmAkea, Inc. from Bay City Capital LLC and Celgene Corporation for $17.4 million CI
More news
Managers TitleAgeSince
Director of Finance/CFO 55 18-06-30
President 53 19-11-19
Director/Board Member - 19-11-19
Members of the board TitleAgeSince
President 53 19-11-19
Director/Board Member 48 19-11-19
Director/Board Member - 19-11-19
More insiders
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Celgene - Nasdaq